CD1D and cancer: Furthermore, iNKT cells derived from cancer patients release reduced levels of IFN-γ as they tend to exhibit a Th2 phenotype and CD1d expression can be downregulated in tumours, which abrogates the efficacy of the direct iNKT cell-mediated immune response (46).